الصفحة 2
الصفحة 2
In vivo Models of HIV Disease and Control
An AIDS vaccine is still elusive and HIV treatment continues to develop multidrug resistance at alarming rates. Because of the similarities between HIV and immune deficiency infections in a variety of animals, it is only natural that scientists use these animals as models to study pathogenesis, treatment, vaccine development and many other aspects of HIV. Part of the series Infectious Agents and Pathogenesis, this volume reviews the immune deficiency virus in a variety of hosts. Pathogenesis, vaccine and drug development, epidemiology, and the natural history of the monkey, mouse, cat, cow, horse, and other animal viruses are detailed and compared to HIV. Also included are chapters on the history and future of animal models, as well as a chapter on ethical and safety considerations in using animal models for AIDS studies.
In Vitro Drug Release Testing of Special Dosage Forms
Covers the in vitro release testing of: lipid based oral formulations; chewable oral drug products; injectables; drug eluting stents; inhalation products; transdermal formulations; topical formulations; vaginal and rectal delivery systems and ophthalmics. The book concludes with a look at regulatory aspects. Covers both oral and non-oral dosage forms Describes current regulatory conditions for in vitro drug release testing Features contributions from well respected global experts in dissolution testing
In Silico Dreams : How Artificial Intelligence and Biotechnology Will Create the Medicines of the Future
In Silico Dreams: How Artificial Intelligence and Biotechnology Will Create the Medicines of the Future delivers an illuminating and fresh perspective on the convergence of two powerful technologies: AI and biotech. Accomplished genomics expert, executive, and author Brian Hilbush offers readers a brilliant exploration of the most current work of pioneering tech giants and biotechnology startups who have already started disrupting healthcare.
High performance computing for drug discovery and biomedicine
Explores the application of high-performance computing (HPC) technologies to computational drug discovery (CDD) and biomedicine. Collects CDD approaches that, together with HPC, can revolutionize and automate drug discovery process, such as knowledge graphs, natural language processing (NLP), Bayesian optimization, automated virtual screening platforms, alchemical free energy workflows, fragment-molecular orbitals (FMO), HPC-adapted molecular dynamic simulation (MD-HPC), and the potential of cloud computing for drug discovery. And delves into computational algorithms and workflows for biomedicine, featuring an HPC framework to assess drug-induced arrhythmic risk, digital patient applications relevant to the clinic, virtual human simulations, cellular and whole-body blood flow modeling for stroke treatments, prediction of the femoral bone strength from CT data, and many more subjects.
Herbal pharmacopeia : Nanotechnology and advancing drug
Explores the intersection between traditional herbal medicine and cutting-edge nanotechnology. The chapters introduce modern techniques used in herbal extraction and analysis. The principles of drug discovery from plants are discussed, with a focus on the identification and development of bioactive compounds that have therapeutic potential. It discusses the pharmacological properties, biotechnological approaches in drug development, and challenges in the formulation and standardization of herbal medicines. Emerging trends and applications of nanotechnology in herbal pharmacotherapy, such as nanoparticle synthesis, enhanced bioavailability using nanocarriers, safety assessments, novel and targeted delivery systems, and regulatory considerations, are thoroughly discussed. Additionally, it includes a comparative analysis of traditional and nano-formulated approaches and their implementation in clinical settings. Towards the end, the book reviews the regulatory considerations for herbal products and future perspectives in herbal pharmacopeia. This book is intended for researchers, clinicians, and professionals in herbal medicine, pharmacology, and nanotechnology.
GPCRs as Therapeutic Targets ; 2-Vol. Set
Delivers an authoritative and in-depth compendium of a vibrant and active area of academic and industrial drug discovery. The book serves as an important reference for new and experienced researchers studying G protein-coupled receptors and discusses the molecular pharmacology of this important target class. It also includes up-to-date material on GPCR structures and structure-based drug design.
Fundamentals of drug development
Discusses how to conduct pharmaceutical research and the context for how the industry fits into global healthcare. Holistically, the well-qualified author helps readers and students of drug development appreciate the time and expense of the process. Specifically, the work identifies the emerging trends shaping the future of drug development, along with important related topics like generic drugs, data sharing, and collaboration.
Frontiers in Anti-Infective Drug Discovery ; Vol.9
Covers a range of topics including rational drug design and drug discovery, medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. Frontiers in Anti-Infective Drug Discovery is a valuable resource for pharmaceutical scientists and post-graduate students seeking updated and critically important information for developing clinical trials and devising research plans in this field. The ninth volume of this series features 5 reviews that cover some aspects of clinical and pre-clinical antimicrobial drug development, with 2 chapters focusing on drugs to treat leishmaniasis and dengue fever, respectively. - Use of preclinical and early clinical data for accelerating antimicrobial drug development - Post-translational modifications: host defence mechanism, pathogenic weapon, and emerged target of anti-infective drugs - Scope and limitations on the potent antimicrobial activities of hydrazone derivatives - Current scenario of anti-leishmanial drugs and treatment - Dengue hemorrhagic fever: the potential repurposing drugs
Formulating poorly water soluble drugs
A pharmaceutical scientist’s approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound’s physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at a minimum a working knowledge of each of the above mentioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop.
Flow and microreactor technology in medicinal chemistry
The ultimate dream for medicinal chemists is the ability to synthesize new drug-like compounds with the push of a button. The key to synthesizing chemical compounds more quickly and accurately lies in computer-controlled technologies that can be optimized by machine learning. Recent developments in computer-controlled automated syntheses that rely on miniature flow reactors—with integrated analysis of the resulting products—provide a workable technology for synthesizing new chemical substances very quickly and with minimal effort.
Ethnobotany : A phytochemical perspective
Explores the chemistry behind hundreds of plant medicines, dyes, fibers, flavors, poisons, insect repellants, and many other uses of botanicals. Bridging the gap between ethnobotany and chemistry, this book presents an introduction to botany, ethnobotany, and phytochemistry to clearly join these fields of study and highlight their importance in the discovery of botanical uses in modern industry and research. Part I. Ethnobotany, explores the history of plant exploration, current issues such as conservation and intellectual property rights, and a review of plant anatomy. An extensive section on plant taxonomy highlights particularly influential and economically important plants from across the plant kingdom. Part II. Phytochemistry, provides fundamentals of secondary metabolism, includes line drawings of biosynthetic pathways and chemical structures, and describes traditional and modern methods of plant extraction and analysis. The last section is devoted to the history of native plants and people and case studies on plants that changed the course of human history from five geographical regions: Africa, the Americas, Asia, Europe, and Ocean. Throughout the entire book, vivid color photographs bring science to life, capturing the essence of human botanical knowledge and the beauty of the plant kingdom.
Ethics and Drug Resistance : Collective Responsibility for Global Public Health
This book provides in-depth analysis of the wide range of ethical issues associated with drug-resistant infectious diseases.
Entry Inhibitors in HIV Therapy
The introductory chapters of this book present an overview of entry inhibitors, review current knowledge of how Env mediates entry, and discuss the challenge of genetic diversity in this region of the viral genome. Subsequent chapters feature current information on individual classes of entry inhibitors that target each step of the virus entry pathway, from attachment to membrane fusion. There is an emphasis on the complex determinants of entry inhibitor susceptibility, resistance mechanisms, the need for clinical phenotyping, and how these issues create new challenges for antiretroviral therapy. Encouraging pre-clinical studies of entry inhibitors as microbicidesare also discussed. The final chapters highlight the current status of entry inhibitors in clinical studies, the major milestone achieved with FDA approval of enfuvirtide, and review drug development, past and present.
Drug utilization research : Methods and applications
Drug Utilization Research (DUR) is a discipline which combines aspects of pharmacotherapy, epidemiology, and health services research into an interdisciplinary set of methods for analyzing and assessing the prescribing, dispensing and consumption of medicines. It combines both qualitative and quantitative approaches to facilitate the safe and effective use of pharmaceuticals. Drug Utilization Research: Methods and Applications provides a comprehensive introduction to this discipline, prepared by an international team of authors with broad experience in numerous fields. Now reorganized and updated to reflect the latest research and global challenges, it is an indispensable resource for understanding the use of pharmaceuticals.
Drug target selection and validation
Focuses on the computational aspects of early drug discovery, drug target identification, and validation. It revises current classical paradigms in target and phenotypic-based drug design with still ingrained approximations and concepts and discusses the research in the new network approach concept that include kinetic selectivity and metabolic analysis. Many often-overlooked approximations and concepts in drug discovery are fully covered. Drug Target Selection and Validation includes both introductory sections and research-based sections to be of use to both students and research scientists in drug discovery, design, kinetics and metabolic analysis. Pharmaceutical scientists, pharmaceutics, drug developers, pharmacologists, biomedical researchers in computer science, medicinal chemists, and precision medicine developers benefit from the information provided. The book concludes with a chapter on chemical and structural databases.
Drug Selectivity : An Evolving Concept in Medicinal Chemistry
Provides a current overview and comprehensive compilation for medicinal chemists that discusses the effects of aiming for multiple targets on the entire drug development process. The result is a broad survey of current and future strategies for drug selectivity in medicinal chemistry with theoretical but also practical aspects. Different strategies are presented and evaluated, such as various design approaches, merged multiple ligands, discovery technologies and a broad range of successful examples of unselective drugs taken from all major disease areas. With its wide-ranging view of an emerging new paradigm in drug development, this handbook is of prime importance for every medicinal and pharmaceutical chemist.
Drug safety evaluation : Methods and protocols
Focuses on the most recent advances in the field of drug safety evaluation. Divided into seven parts, chapters detail specific aspects related to the experimental design of preclinical studies conducted to support the safety of pediatric and combination drugs, necropsy and histopathology evaluation, mass spectrometry imaging, genetic toxicology protocols including the Pig-a mutation assay, safety pharmacology methods such as automatization of patch-clamp procedures, target safety assessment for investigative toxicology, screening assays for developmental toxicology, and methods to characterize novel translational safety biomarkers like microRNAs. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting to avoid known pitfalls.
Drug repurposing : A new fashion for a new hope
The repurposing of drugs is becoming increasingly attractive as it avoids the long process and cost implications associated with bringing a novel drug to market i.e., drug repurposing is cost effective and time saving. This study will discuss the repositioning of several drugs that belong to different pharmaceutical classifications such as antimicrobials (itraconazole and fluoroquinolones), anti-diabetic agents (metformin and sodium glucose co-transporter 2 inhibitors), cardiovascular drugs (β-blockers and digoxin), anticonvulsants (topiramate), immunosuppressants (sirolimus), non-steroidal anti-inflammatory drugs (NSAIDs e.g., COX inhibitors), and cholesterol lowering drugs (statins).
Drug interactions in infectious diseases : Mechanisms and models of drug interactions
Provides a comprehensive review of basic clinical pharmacology with a focus on metabolism and transporter-mediated drug interactions. The chapters address materials that cannot be retrieved easily in the medical literature, including materials focused on the complex interrelationship of acute infection, inflammation, and the risk of drug interactions in the Drug-Cytokine chapter. The Food-Drug and Herb-Drug interactions chapters remain definitive resources. A new chapter on in vitro modeling of drug interactions is included along with updates on design and data analysis of clinical drug interaction studies. Authoritative discussion of models for regulatory decision-making on drug-drug interactions provides the necessary framework to aid antimicrobial drug development. This concise review of the mechanisms and models of drug interactions provides important insights to health care practitioners as well as scientists in drug development
Drug interactions in infectious diseases : Antimicrobial drug interactions
Delivers a quick clinical resource that distills relevant drug interactions by antimicrobial drug class. The book provides informative tables on specific drug-drug interactions that include the degree and severity of the expected interaction. A mechanistic basis for drug-drug interactions is also provided to link observed interactions to pharmacologic characteristics of key drug classes. This complete resource is organized by major antibacterial, antimycobacterial, antiviral, antifungal, antimalarial, and antiprotozoal class. In line with current innovations in antimicrobial drug development, a distinct chapter on the pharmacologic management of drug interactions in hepatitis B virus (HBV) and hepatitis C virus (HCV)-related infections is included. Two new chapters are dedicated to the management of human immunodeficiency virus (HIV) drug-drug interactions given the breadth of antiretroviral class-specific effects. This comprehensive review of known drug interactions and strategies to manage them is an invaluable resource to all health care practitioners.
